Increased risk of myelotoxicity in elderly patients with non-hodgkin lymphoma - The case for routine prophylaxis with colony-stimulating factor beginning in the first cycle of chemotherapy

被引：37

作者：

Balducci, L

Repetto, L

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Senior Adult Oncol Program, Tampa, FL 33612 USA

[2] Ist Nazl Riposa & Cura Anziani, Unita Operat Geriatria Oncol, Rome, Italy

来源：

CANCER | 2004年 / 100卷 / 01期

关键词：

myelotoxicity; neutropenia; elderly; chemotherapy; colony-stimulating factor (CSF); non-Hodgkin lymphoma (NHL);

D O I：

10.1002/cncr.11861

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neutropenia is the major dose-limiting toxicity of myelosuppressive chemotherapy in patients with cancer. Because of the high incidence of neutropenic complications and death in the early cycles of chemotherapy and the potential for improved outcomes, prophylaxis with colony-stimulating factor beginning in the first cycle should be routinely considered in elderly patients with non-Hodgkin lymphoma who are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy regimens.

引用

页码：6 / 11

页数：6